This statement summarizes the exis...

This statement summarizes the existing U.S. Preventive Services Task Force (USPSTF) recommendation in succession screening for lung cancer and the supporting scientific evidence, and it updates the 1996 recommendations contained in the Guide to Clinical Preventive Services, 2d ed (1) In 1996, the USP-STF commited against screening for lung cancer ("D" recommendation). The task force now uses an explicit proces in which the balance of benefits and harms is determined exclusively according to the quality and magnitude of the evidence. As a inference current letter grades are based upon different criteria than those in 1996 Explanations of the ratings and of the solidity of overall evidence are given in Tables 1 and 2 respectively. The whole information on which this statement is based, including evidence tables and hints is available in the summary of the evidence (2) and in the systematic evidence review (3) onward this topic, available through the USPSTF Web site (http://www.preventiveservices.ahrq.gov) and [i]or[/i] part of to the other the National Guideline Clearinghouse (http://www.guideline.gov). The summary of the evidence and the recommendation statement also are available in print by means of the Agency for Healthcare Research and Quality Publications Clearinghouse between the walls of subscription to the Guide to Clinical Preventive Services, 3d ed: Periodic Updates. To order, contact the Clearinghouse (telephone: 800-358-9295; e-mail: ahrqpubs@ahrq.gov).

This recommendation first appeared in Ann Intern M 2004;140:738-9

Summary of Recommendation

* The USPSTF decides that the evidence is insufficient to approve for or against screening asymptomatic somebodys for lung cancer with either low-dose comput tomography (LDCT) chest radiographs, sputum cytology, or a combination of these touchstones I recommendation.

The USPSTF raise fair evidence that screening with LDCT chest radiographs, or sputum cytology can ascertain lung cancer at an earlier stage than lung cancer would be bring to lighted in an unscreened population; however, the USPSTF originate poor evidence that any screening strategy for lung cancer decreases mortality. Because of the invasive nature of diagnostic testing and the possibility of a high number of false-positive experiments in certain populations, there is potential for significant harms from screening. Therefore, the USPSTF could not determine the balance between the benefits and harms of screening for lung cancer.

Clinical Considerations

* The benefit of screening for lung cancer has not been established in any form into groups including asymptomatic high-risk populations so as older smokers. The balance of harms and benefits becomes increasingly unfavorable for parts at lower risk, such as nonsmokers.

* The sensitivity of LDCT for detecting lung cancer is four times greater than the sensitivity of chest radiographs. However, LDCT also is associated with a greater number of false-positive inferences more radiation exposure, and increased charges compared with chest radiographs.

* Because of the high rate of false-positive ensues many patients will undergo invasive diagnostic performances as a result of lung cancer screening. Although the morbidity and mortality rates from these manner of proceedings in asymptomatic patients are not available, mortality rates from complications of surgical interventions in symptomatic patients reportedly range from 13 to 116 percent; morbidity rates range from 88 to 44 per-cent with higher rates associated with larger resections.

* Other potential harms of screening are potential anxiety and belong to as a result of false-positive standards as well as possible false reassurance because of false-negative eventuates However, these harms have not been adequately studied.

Discussion

Lung cancer is the next to the first leading cancer in the United States and the leading cause of cancer-related death in men and women In 2003 approximately 157200 lung cancer-associated deaths were predicted in the United States. (4) Incidence of lung cancer increases with age. (5) Although cigarette smoking is the major risk factor for lung cancer, (6) other risk factors include family history, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, environmental radon outlook passive smoking, asbestos exposure, and certain occupational outlooks (3) For a given amount of tobacco position some studies suggest that women are at higher risk for developing lung cancer than men (7) Women attend to develop adenocarcinoma of the lung disproportionately to men (8) and adenocarcinoma watchs to occur peripherally, making it more readily visible upon radiography. Lung cancer has a poor prognosis; steady with advances in therapy, average five-year survival rates are les than 15 per-cent in all patients with lung cancer. (4) Five-year survival ranges from 70 percent in patients with stage I disease to les than 5 percent in patients with stage IV disease. (9)

The USPSTF examined the evidence for the accuracy of screening proofs for lung cancer (i.e., LDCT chest radiographs with or without sputum cytology) in the general population as well as the high-risk population. The sensitivity and specificity of chest radiographs for diagnosing lung cancer are 26 and 93 percent respectively, with a positive predictive value of 10 percent for an abnormal chest radiograph (estimates based forward LDCT as the gold standard). (10) The false-positive rate of LDCT (defined as number of patients with abnormal LDCT requiring further evaluation who do not have cancer) ranges from 5 to 41 percent (3) greatest in number abnormalities found on LDCT are resolv forward high-resolution computed tomography. This wide range of false-positive follows is likely to be because of underlying differences, of the like kind as prevalence of pulmonary fungal infections, in the populations studied. principally of the patients (63 to 90 percent) with abnormalities institute on high-resolution computed tomography subsequently are institute to have cancer. (3)